This study was undertaken to evaluate the differences in chronotherapeutic effects of angiotensin-II receptor blockers, valsartan and olmesartan in hypertensive patients with non-dipper blood pressure (BP) pattern during valsartan at morning. Ninety four patients were enrolled, and 40 patients were judged to be non-dippers. In these patients, same dose of valsartan was changed to evening (Val-E, n ¼ 12), or olmesartan (equivalent dose of valsartan) was given at morning (Olm-M, n ¼ 13) or evening (Olm-E, n ¼ 15) for 4 months. BP decreased during sleep and increased during waking hours in Val-E group. In Olm-M and Olm-E groups, BP decreased during sleep and waking hours. Percent reduction in BP at night-time compared to BP at waking hours significantly increased after changing the dose regimen in each group. Serum creatinine decreased and estimated glomerular filtration rate (eGFR) elevated in Olm-M and Olm-E, but not Val-E groups. Positive correlation between systolic BP (SBP) during sleep and serum creatinine, and negative correlation between SBP during sleep and eGFR were detected. These data suggest that dipper BP pattern could be obtained by chronotherapeutic approach using valsartan and olmesartan in non-dipper patients with valsartan at morning. Morning and evening olmesartan, but not evening valsartan improved renal function in these patients.
Introduction
Chronotherapy is a pharmacologic approach whereby a drug is given at a time that varies according to physiologic needs. Our previous study using stroke-prone spontaneously hypertensive rats (SHR-SP) showed that blood pressure (BP)-lowering effect of valsartan [an angiotensin-II receptor blocker (ARB)] was longer after dosing at an inactive period than after dosing at an active period and, consequently, the survival period of the animals was longer after dosing at an inactive period (1) . However, such effects based on the time of dosing were not observed for another ARB, olmesartan in this animal study. Duration of BP-lowering effect in SHR-SP and prolongation of their survival period after dosing olmesartan at an active period were similar to those after dosing the drug at an inactive period (1) . These animal data led us to speculate that the chronotherapeutic effects of valsartan were different from those of olmesartan in hypertensive patients.
There are precedents for chronotherapy in hypertension in clinical practice. For example, Hermida et al. reported that, in untreated hypertensive patients with a non-dipper BP pattern, a dipper BP pattern was obtained in 24% and 75% of patients after dosing of valsartan in the morning and evening, respectively (2) .
Recent advances in ambulatory blood pressure monitoring (ABPM) have demonstrated that a higher night-time BP and a non-dipper BP pattern are good predictors of cardiovascular events (3, 4) and progression of renal disease (5, 6) . Cardiovascular morbidity and mortality are also reported to elevate in hypertensive patients with a non-dipper BP pattern even under antihypertensive drugs (7) . These data suggest that it is important for changing a nondipper to dipper BP pattern in hypertensive patients. Previous studies showed that switching dosing-time of antihypertensive drugs for morning to evening in patients with a non-dipper BP pattern during morning treatment caused more BP reduction at night-time and increased a number of dipper BP pattern (8e10).
Valsartan is one of ARBs, which are frequently prescribed for the treatment of hypertension and improve the prognosis of patients. However, a non-dipper BP pattern is detected in half (46~58%) of hypertensive patients after dosing of valsartan in the morning (11, 12) , and therefore, a chronotherapeutic approach might provide a benefit for these patients. To address the issue and potential chronotherapeutic differences between valsartan and olmesartan, this study was performed in hypertensive patients with a nondipper BP pattern during morning treatment with valsartan as follows; 1) a dosing-time was switched from morning to evening, and 2) ARB was changed to olmesartan, which was given at morning or evening. To evaluate a benefit of chronotherapy, the influences on BP pattern and renal function were determined in each group.
Methods
The study protocol was approved by the Ethics Review Board of Jichi Medical University (Tochigi, Japan), and registered with the University Hospital Medical Information Network Clinical Trials Registry, Tokyo, Japan (registration number UMIN000003776). This study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each patient.
Hypertension was defined as systolic BP (SBP) ! 140 mmHg and/or diastolic BP(DBP) ! 90 mmHg at clinic. The definition of night-time BP dipping was based on SBP; night SBP > day SBP as a "riser", and [1-night SBP/day SBP] Â 100 (%): 0 ratio <10 as a "non-dipper"; 10 ratio <20 as a "dipper", and 20 ratio as an "extreme dipper" (13) .
The inclusion criteria were as follows; (i) Hypertensive patients took 40e160 mg valsartan once daily in the morning for >2 months; (ii) Dose regimens of valsartan and other antihypertensive drugs were not altered for >2 months, and clinic BP was well controlled (SBP <140 mmHg and DBP <90 mmHg in nondiabetic patients, and SBP <130 mmHg and DBP <80 mmHg in diabetic patients); (iii) Identical dose regimens for hypertension and comorbidities could continue for the following 4 months; (iv) Shift workers were not included; (v) Patients had a non-dipper BP pattern during morning dosing of valsartan.
Patients
All patients were active during day-time, and took a rest during night-time. Ninety four hypertensive patients were enrolled in the study (Fig. 1 ). Patients were initially diagnosed as being hypertensive based on clinic BP measurement. The dosing-time of valsartan and other antihypertensive drugs was morning in all patients, except for two patients: one took azelnidipine in the morning and evening, and another took amlodipine at bedtime.
Study design
The study had a multicenter, open-label, randomized, parallelgroup design. The 24-h assessment of BP was done with a portable automatic ABPM device (TM-2431; A&D Co., Ltd., Tokyo, Japan). BP measurements were taken every 30 min from 6 am to 10 pm, and every 60 min from 10 pm to 6 am, to obtain 24-h, day-time, and night-time data. BP data were analyzed using software (TM-2430; A&D Co., Ltd.). "Day-time" and "night-time" were judged based on the diary of each patient.
Two patients withdrew their consent to be included in the study (Fig. 1) . The first 24-h BP was assessed in the remaining 92 subjects: 52 patients were judged to be "dippers" and the remaining 40 patients to be "non-dippers". The latter (40/92; 43%) were divided randomly into valsartan-evening dosing (valsartan-E) (n ¼ 12), olmesartan-morning dosing (olmesartan-M) (n ¼ 13) and olmesartan-evening dosing (olmesartan-E) (n ¼ 15) groups. The inhibitory action of olmesartan on angiotensin-II labeled with iodine-125 bound to the angiotensin-II receptor type 1 is reported to be about fourfold greater than that of valsartan (14) . In clinical practice, the recommended starting dose is 80 mg/day for valsartan and 20 mg/day for olmesartan (15) . Based on these basic and clinical data, the dose of olmesartan was one quarter that of valsartan in olmesartan-M and olmesartan-E groups (e.g., 80 mg/day of valsartan switched to 20 mg/day of olmesartan). An adherence to treatment was checked at every clinic visit.
The second 24-h BP was assessed at 4 months after changing the dose regimen. Serum creatinine was measured at the initiation and end of the study, and the estimated glomerular filtration rate (eGFR, ml/min/1.73 m 2 ) was calculated as follows; 194 Â serum creatinine À1.094 Â age À0.287 Â 0.739 (if female) (16) .
Acceptable criteria of ABPM were (i) >24 h measurement and (ii) at least 80% of available readings. Patients who completed the protocol without changing antihypertensive drugs and had good adherence without changing other drugs were included for analysis. Seventy-seven patients completed the study (Fig. 1) , and their data were analyzed.
Statistical analyses
This study was performed by pre-post comparison design, because there was not a non-dipper group who continued to take valsartan in the morning as a control. It was estimated that an enrollment of 10 patients per group would provide a power of at least 80% (alpha ¼ 0.05, two-sided) to detect 10% decline of nighttime BP status compared to the baseline, with 10% of standard deviation.
Characteristics of patients (other than age and body weight) were analyzed by Fisher's exact test, followed by pairwise comparisons. Age and body weight, and profiles of BP at the initiation of the study were compared by one-way analysis of variance with post-hoc BonferronieDunn test.
Changes in BP, serum creatinine and eGFR were compared using the paired t-test (the baseline vs. 4 months). Correlation between BP and serum creatinine (or eGFR) was assessed using Pearson's correlation coefficient. p < 0.05 was considered significant. All calculations were undertaken using SPSS ver11 (SPSS Japan, Tokyo, Japan) and EZR (a modified version of R commander, Saitama Medical Center, Jichi Medical University, Saitama, Japan). b-blocker
Table 2
Profiles of blood pressure (BP) at the initiation and end of the study.
Reference group Randomization group
At the initiation of the study Duration of sleep (h) 7. 
Results
In this study, mean number of observation points obtained for calculation of BP dipping was 33 during waking hours and 8 during sleep. The availabilities of ABPM measurements during waking hours and sleep were more than 95%.
The characteristics of hypertensive patients and BP profiles at the initiation of the study are shown in Tables 1 and 2 . The percentage of hypertensive patients with diabetes mellitus was significantly (p < 0.05) greater in the olmesartan-E group (33%) than in the valsartan-M group (5%). While the percent reduction in SBP at night-time compared to SBP at waking hours was significantly (p < 0.01) lower and SBP during sleep was significantly (p < 0.01) higher in the valsartan-E, olmesartan-M and olmesartan-E groups than in the valsartan-M group, SBP during waking hours and mean 24-h SBP did not significantly differ among the four groups. No significant differences were observed in any parameters (the characteristics of patients and BP profiles at the initiation of the study shown in Tables 1 and 2 ) among the valsartan-E, olmesartan-M and olmesartan-E groups.
BP profiles at the end of the study are also shown in Table 2 .
Comparing BP values between before and after changing the dose regimen in each group, the changes in mean value of BP at the end of the study were À4.1 mmHg (SBP) and À2.2 mmHg (DBP) during sleep, and þ7.9 mmHg (SBP) and þ4.2 mmHg (DBP) during waking hours in the valsartan-E group (Fig. 2a) . In the olmesartan-M and olmesartan-E groups, the mean value of BP decreased significantly during sleep (SBP, À11.1 mmHg, DBP, À7.4 mmHg, p < 0.01 and SBP, À8.3 mmHg, p < 0.05, respectively) (Fig. 2b, c) . The changes in mean value of BP during waking hours were À3.7 mmHg (SBP) and À3.1 mmHg (DBP) in the olmesartan-M group, and were À1.4 mmHg (SBP) and þ0.4 mmHg (DBP) in the olmesartan-E group. The percent reduction in SBP during night-time compared to SBP during waking hours significantly increased at 4 months after changing the dose regimen in each group as follows; 2.4 ± 6.3 to 10.5 ± 3.8% in the valsartan-E (p < 0.01), 4.3 ± 4.0 to 10.1 ± 6.4% in the olmesartan-M (p < 0.05) and 1.2 ± 5.0 to 6.4 ± 10.4% in the olmesartan-E (p < 0.05) groups (Fig. 3) . The number of patients with a dipper BP pattern was 7/11 (64%) in the valsartan-E, 5/11 (46%) in the olmesartan-M and 5/12 (42%) in the olmesartan-E groups. Serum creatinine slightly, but significantly decreased (p < 0.05) in the olmesartan-treated groups, and eGFR significantly elevated (p < 0.05) in the olmesartan-M group and tended to elevate (p ¼ 0.06) in the olmesartan-E group after dosing the drug for 4 months (Table 3) . Renal function was not significantly improved in the valsartan-E group. Positive correlations were detected between SBP during sleep and serum creatinine in all (p < 0.05) and non-dipper (p ¼ 0.06) patients (Fig. 4a) . In addition, there were negative correlations between SBP during sleep and eGFR in all (p < 0.05) and non-dipper (p < 0.05) patients (Fig. 4b) . No significant correlations were observed between other BP measurements (SBP during waking hours, DBP during sleep and waking hours, 24-h SBP and DBP) and serum creatinine (or eGFR).
Discussion
In this study, the percentage of patients with a non-dipper BP pattern given a morning dose of valsartan for >2 months was 43.5%, which is similar to those reported in other studies (45.7e57.8%) (11, 12) .
The effect of antihypertensive drugs can be influenced by a dosing-time, and appropriate timing of dosing is likely to correct an abnormal BP pattern (17) . Chronotherapeutic studies in patients with a non-dipping BP pattern have shown that switching all antihypertensive drugs from morning to evening dosing, or adding a new drug in the evening, corrected the abnormal BP pattern in 15% and 41% of patients, respectively (9, 10) . In this study, in hypertensive patients with a non-dipper BP pattern, a dipper BP pattern was obtained in 64% of subjects after switching from morning to evening dosing of valsartan without changing its dose. Thus, this study also showed that the chronotherapeutic approach of valsartan could change a non-dipper BP pattern in hypertensive patients during morning treatment with the drug to a dipper BP pattern.
SBP slightly decreased during sleep (mean, À4.1 mmHg) after switching from morning to evening dosing in the valsartan-E group. However, SBP slightly increased during waking hours (mean, þ7.9 mmHg), and consequently, the dipping state was improved in this group. Dipper BP patterns were also obtained in 42e46% of patients in olmesartan-treated groups. In contrast to the valsartan-E group, SBP significantly decreased during sleep and slightly decreased during waking hours in the olmesartan-M and olmesartan-E groups. Therefore, it is likely that the influence of valsartan after evening dosing on daily BP pattern was different from those of olmesartan after morning and evening dosings under the present condition. Our previous study in SHR-SP rats showed that plasma concentrations of valsartan after dosing during an inactive period were higher than those after dosing during an active period, which in turn caused the dosing time-dependent changes in the duration of BP-lowering effects (1). However, although plasma concentrations of olmesartan also varied with a dosing-time, the duration of BP-lowering effects were not influenced (1). Compared with valsartan, olmesartan is reported to dissociate slowly from the AII receptors of vascular tissue (14) , which partially explains the chronotherapeutic differences between valsartan and olmesartan observed in the previous animal and present human studies.
The chronotherapeutic effects of olmesartan in hypertensive patients have been published, and conflicting data observed. Some research groups (18, 19) found that, compared with morning dosing, evening dosing of olmesartan was a better dose regimen for the treatment of hypertension, whereas other research groups (20, 21) did not support the merits of chronotherapy of olmesartan. In this study, the percent of dipper BP pattern was similar between the olmesartan-M (46%) and olmesartan-E (42%) groups, which suggests that the influence of a dosing-time of olmesartan on BP dipping state was small in hypertensive patients with a non-dipper BP pattern during valsartan treatment at morning. We do not have definitive explanations for apparent diverse findings, and further clinical studies are needed to confirm the chronotherapeutic effects of olmesartan.
The previous study showed that the duration of the antihypertensive effect of valsartan was longer after dosing during an inactive period than after dosing during an active period in SHR-SP and, consequently, the survival period of the rats was longer after dosing during an inactive period (1) . In addition, such chronotherapeutic effects were not detected for olmesartan in the animal study. Based on these animal data, we speculated that the protective effect of valsartan (but not olmesartan) against hypertension-induced organ damage differs between morning and evening dosings. In this study, a non-dipper BP pattern was corrected in 64% of the patients in the valsartan-E group, and therefore, we anticipated that renal function might be improved after switching from morning to evening dosing. However, serum creatinine did not significantly decrease or eGFR did not significantly increase at 4 months after switching the dose regimen in the valsartan-E group. Elevated night-time BP (especially SBP) (5, 22) and a non-dipper BP pattern (23) are potent risk factors for declines in GFR. However, whether a reduction of night-time BP or a dipper BP pattern can be a therapeutic target to prevent progression of renal disease should still be better defined (6) . After switching from morning to evening dosing, SBP slightly decreased during sleep and slightly increased during waking hours in the valsartan-E group, and consequently, the dipping state was improved in this group (64%). On the other hand, dipper BP patterns were detected in 46% of patients in the olmesartan-M group and in 42% of patients in the olmesartan-E group. However, in contrast to the valsartan-E group, serum creatinine decreased and eGFR increased in the olmesartan-M and-E groups. SBP during sleep significantly decreased in the olmesartan-M and olmesartan-E groups. In addition, a positive correlation between SBP during sleep and serum creatinine, and a negative correlation between SBP during sleep and the eGFR were detected. Based on these data, it is speculated that, although a dipper BP pattern was obtained in many patients in the valsartan-E group, BP reduction at night was too small to improve renal function under the present condition, which is comparable with the idea that a reduction of night-time BP rather than a dipper BP pattern is more adequate target to prevent progression of renal disease. Hermida et al. reported that the dosing of valsartan at bedtime reduced BP during sleep and improved renal function in hypertensive patients (12) , findings which were different from those in this study. However, the daily dose of valsartan was 160 mg in their study and 40e80 mg in this study, which could have caused the diverse chronotherapeutic effects of valsartan. Therefore, whether the chronotherapeutic effects of valsartan are altered by the dose of the drug remains to be determined.
Limitation of this study
The number of patients was relatively small in this study, which might lead to an incorrect conclusion. In addition, because the changes in serum creatinine and eGFR after changing the dose regimen were small, it remains to be determined whether the chronotherapeutic approach improves the prognosis of these patients. Further study with a longer duration in a larger number of patients is needed to confirm the chronotherapeutic differences between valsartan and olmesartan.
In summary, the present findings suggest that a dipper BP pattern could be obtained after switching from morning to evening dosing of valsartan, and switching to morning and evening dosing of olmesartan, in hypertensive patients with a non-dipper BP pattern during morning treatment with valsartan. Morning and evening olmesartan, but not evening valsartan improved renal function in these patients. Therefore, it is speculated that, in hypertensive patients with a non-dipper BP pattern during morning treatment with valsartan, an increased dose of the drug is needed to improve renal function, irrespective of dosing-time. On the other hand, olmesartan (equivalent dose of valsartan) might improve renal function after dosing at morning or evening in these patients. Fig. 4 . Correlation between SBP during sleep, and (a) serum creatinine and (b) eGFR in all patients and non-dipper patients during morning dosing of valsartan. Data at the initiation and end of the study were included. For the dipper patients (valsartan-M group), only the values at the initiation of the study were available because 2nd ABPM was not performed at the end of the study in this group.
